Results 181 to 190 of about 70,724 (301)

Exploration of Pathways for Integrating Health into All Policies from the Perspective of Environmental Health Governance in China. [PDF]

China CDC Wkly
Yang X, Fang H, Wang Q, Xu D.
europepmc   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Efficacy and compliance of an administrative MDT-driven antimicrobial prophylaxis protocol in Class I incisions: a retrospective-prospective study. [PDF]

Front Public Health
Li Y, Wang J, Wen L, Li N, Wang J, Liu Z, Zhang X, Fan K, Meng X.   +8 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Inflation, Race, and Legislation-The Erosion in the Real Value of Monetary Compensation for Miners' Occupational Lung Disease in South Africa, 1973-2024. [PDF]

Am J Ind Med
Nicol M, teWaterNaude J, Kistnasamy B, Ehrlich R.   +3 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Retraction: Low-dose chest CT for diagnosing and assessing the extent of lung involvement of SARS-CoV-2 pneumonia using a semi quantitative score. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

IMPLEMENTATION OF INTERNATIONAL STANDARDS OF ADMINISTRATIVE LEGISLATION IN THE LEGISLATION OF UKRAINE

Law Bulletin, 2023
openaire   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Strengthening natural hazard preparedness in Nepal: insights from stakeholder and community engagement. [PDF]

Glob Health Action
Bhatta S, Mytton J, Joshi SK, Pant PR, Adhikary P, Adhikari BR, Gautam S, Powell J, Teijlingen EV.   +8 more
europepmc   +1 more source